Sidransky Ellen, LaMarca Mary E, Ginns Edward I
Section on Molecular Neurogenetics, Medical Genetics Branch, National Human Genome Research Institute, NIH, Building 35, Room 1A213, 35 Convent Drive, MSC 3708, Bethesda, MD 20892, USA.
Mol Genet Metab. 2007 Feb;90(2):122-5. doi: 10.1016/j.ymgme.2006.09.007. Epub 2006 Nov 3.
While enzyme replacement therapy for Gaucher disease has been widely used and appears to be an efficacious and safe treatment, this success should not be a reason for complacency. Other treatment strategies currently under consideration for patients with Gaucher disease include gene therapy, substrate reduction therapy and chaperone therapy. Furthermore, improvements in enzyme therapy could also have a significant clinical impact. Individuals with Gaucher disease and other lysosomal disorders will greatly benefit from continual refinement and optimization of the current therapy, as well as from the development of new treatment modalities that offer improvements in efficacy, cost, safety and availability.
虽然用于戈谢病的酶替代疗法已被广泛应用,且似乎是一种有效且安全的治疗方法,但这一成功不应成为自满的理由。目前正在为戈谢病患者考虑的其他治疗策略包括基因疗法、底物减少疗法和伴侣疗法。此外,酶疗法的改进也可能产生重大的临床影响。戈谢病和其他溶酶体疾病患者将从当前疗法的持续改进和优化,以及从开发在疗效、成本、安全性和可及性方面有所改进的新治疗方式中大大受益。